Evidence map›Paper›PMID 30965022›Full record

ArticleHuman pathology2019

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

Sook Jung Yun, Shujing Liu, Meghan Buckley, Tao Wang, Suna Jin, Giorgos Karakousis, Madalyn G Peters, David E Elder, Phyllis A Gimotty, Xiaowei Xu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Dormancy of cutaneous melanoma.Cancer cell international · 2024
    Review
  3. Assessment of tumoral and peritumoral inflammatory reaction in cutaneous malignant melanomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sook Jung YunDepartment of Dermatology, Chonnam National University Medical School, Gwangju, 61469, Republic of Korea.
Shujing LiuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Meghan BuckleyDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tao WangOffice of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA.
Suna JinDepartment of Dermatology, Chonnam National University Medical School, Gwangju, 61469, Republic of Korea.
Giorgos KarakousisDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Madalyn G PetersDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
David E ElderDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Phyllis A GimottyDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: pgimotty@mail.med.upenn.edu.
Xiaowei XuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: xug@mail.med.upenn.edu.
University of Pennsylvania · USChonnam National University · KRUnited States Food and Drug Administration · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
Tissue &PathologyP50CA093372 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2001 to 2009
$15.4M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA093372NCI NIH HHS P50 CA174523
6 · The paper itself

Abstract

We observed that non-tumor-infiltrating inflammatory cells are often present in the stroma of melanoma. The role of these stromal inflammatory cells (SIC) in cancer has not been studied. We evaluated the prognostic significance of SIC in 299 patients with vertical growth phase primary melanomas with at least 10 years of clinical follow-up. Lymphatic density and lymphatic invasion in the areas with SIC was quantified. The prognostic significance of these factors was evaluated using univariable and multivariable Cox models for melanoma-specific death and the time to first recurrence. Of the 299 melanomas, 161 exhibited areas with SIC. Percentages of vertical growth phase tumor-infiltrating lymphocytes and radial growth phase regression were significantly higher in cases with SIC compared to those without SIC (P = .005); lymphatic invasion was also detected more frequently in cases with SIC (P = .001). Lymphatic density in SIC areas was higher than that in other areas of the melanomas. Patients with SIC had poorer clinical outcome. Vascular endothelial growth factor-C (VEGFC) staining in a subset of these melanoma patients showed that VEGFC expression in the stromal macrophages was associated with lymphatic invasion in SIC areas. In conclusion, SIC in melanoma is associated with poorer prognosis, and the prognostic effect is partially mediated through induction of lymphangiogenesis with increased lymphatic invasion.

Indexed as

FemaleHumansInflammationLymphocytes, Tumor-InfiltratingMacrophagesMaleMelanomaMiddle AgedPrognosisSkin NeoplasmsStromal CellsVascular Endothelial Growth Factor CVascular Endothelial Growth Factor CCutaneous melanomaLymphatic densityLymphatic invasionMacrophagesStromal inflammatory cellsVEGFC

Identifiers

PMID30965022
PMCPMC6579677
OpenAlexW2927419265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.